These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36662442)

  • 1. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
    Taylor PC; Chen YF; Pope J; Weinblatt M; Mysler E; Rubbert-Roth A; Jia B; Sun L; Liu Y; Holzkämper T; Tanaka Y
    Rheumatol Ther; 2023 Apr; 10(2):463-476. PubMed ID: 36662442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
    Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Östör A; Ng KJ; Gerwien J; Zaremba-Pechmann L; Brnabic AJM; Fautrel B
    Rheumatol Ther; 2023 Dec; 10(6):1575-1595. PubMed ID: 37755648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
    van der Heijde D; Durez P; Schett G; Naredo E; Østergaard M; Meszaros G; De Leonardis F; de la Torre I; López-Romero P; Schlichting D; Nantz E; Fleischmann R
    Clin Rheumatol; 2018 Sep; 37(9):2381-2390. PubMed ID: 30078086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
    Sholter D; Wu J; Jia B; Zhang H; Griffing K; Birt J; Reis PJS; Liu H; Bingham CO
    Rheumatol Ther; 2022 Apr; 9(2):541-553. PubMed ID: 34990002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.
    Caporali R; Taylor PC; Aletaha D; Sanmartí R; Takeuchi T; Mo D; Haladyj E; Bello N; Zaremba-Pechmann L; Fang Y; Dougados M
    Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38258434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
    Genovese MC; Kremer JM; Kartman CE; Schlichting DE; Xie L; Carmack T; Pantojas C; Sanchez Burson J; Tony HP; Macias WL; Rooney TP; Smolen JS
    Rheumatology (Oxford); 2018 May; 57(5):900-908. PubMed ID: 29415145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study).
    Hernández-Cruz B; Rosas J; Díaz-Torné C; Belzunegui J; García-Vicuña R; Inciarte-Mundo J; Pons A; Millán AM; Jeria-Navarro S; Valero JA; García-Castañeda N; Valero C; Llorente I; Calvo A; Díaz-Cerezo S; Núñez M
    Rheumatol Ther; 2022 Apr; 9(2):589-608. PubMed ID: 35041155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
    Guidelli GM; Viapiana O; Luciano N; De Santis M; Boffini N; Quartuccio L; Birra D; Conticini E; Chimenti MS; Bazzani C; Bruschi E; Riva M; Canziani LM; Bianchi G; Pozzi MR; Limonta M; Gorla R; Perricone R; Frediani B; Moscato P; De Vita S; Dagna L; Rossini M; Selmi C
    Clin Exp Rheumatol; 2021; 39(4):868-873. PubMed ID: 33338001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Wells AF; Jia B; Xie L; Valenzuela GJ; Keystone EC; Li Z; Quebe AK; Griffing K; Otawa S; Haraoui B
    Rheumatol Ther; 2021 Jun; 8(2):987-1001. PubMed ID: 34028703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
    King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
    Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.
    Curtis JR; Churchill M; Kivitz A; Samad A; Gauer L; Gervitz L; Koetse W; Melin J; Yazici Y
    Arthritis Rheumatol; 2015 Dec; 67(12):3104-12. PubMed ID: 26316013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
    Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindström U; Turesson C; Frisell T
    Rheumatology (Oxford); 2022 Oct; 61(10):3952-3962. PubMed ID: 35134119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
    Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
    Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis.
    Hernández-Cruz B; Kiltz U; Avouac J; Treuer T; Haladyj E; Gerwien J; Gupta CD; Conti F
    Rheumatol Ther; 2023 Dec; 10(6):1417-1457. PubMed ID: 37715917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
    Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials.
    Fautrel B; Wu J; Wang D; Haladyj E; van de Laar MAFJ; Takeuchi T
    J Clin Rheumatol; 2023 Apr; 29(3):139-144. PubMed ID: 36473106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study.
    Park JW; Kim MJ; Kim HA; Kim JH; Lee EB; Shin K
    Front Med (Lausanne); 2022; 9():839206. PubMed ID: 35211491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.
    Takeuchi T; Genovese MC; Haraoui B; Li Z; Xie L; Klar R; Pinto-Correia A; Otawa S; Lopez-Romero P; de la Torre I; Macias W; Rooney TP; Smolen JS
    Ann Rheum Dis; 2019 Feb; 78(2):171-178. PubMed ID: 30194275
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.